Igbpl is part of a positive feedback loop in stem cell factor-dependent, selective mRNA translation initiation inhibiting erythroid differentiation

Blood

Volumn 112, Issue 7, 2008, Pages 2750-2760

  Grech, Godfrey ^a   Blázquez Domingo, Montserrat ^a   Kolbus, Andrea ^b,c   Bakker, Walbert J ^a   Müllner, Ernst W ^d   Beug, Hartmut ^b   Von Lindern, Marieke ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN BINDING PROTEIN 1; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A; S6 KINASE; STEM CELL FACTOR; UNCLASSIFIED DRUG; ERYTHROPOIETIN; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; ERYTHROBLAST; ERYTHROID CELL; FEEDBACK SYSTEM; GENE CLUSTER; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; POLYSOME; POSITIVE FEEDBACK; PRIORITY JOURNAL; RNA TRANSLATION; SIGNAL TRANSDUCTION; TRANSLATION REGULATION; CELL PROLIFERATION; CLUSTER ANALYSIS; CYTOLOGY; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; GENETICS; METABOLISM; PHOSPHORYLATION; PROTEIN SYNTHESIS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLUSTER ANALYSIS; ENZYME ACTIVATION; ERYTHROBLASTS; ERYTHROID CELLS; ERYTHROPOIETIN; EUKARYOTIC INITIATION FACTOR-4E; FEEDBACK, BIOCHEMICAL; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PHOSPHORYLATION; POLYRIBOSOMES; PROTEIN BIOSYNTHESIS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA, MESSENGER; STEM CELL FACTOR; TRANSFORMING GROWTH FACTOR BETA;

EID: 53449102851     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-01-133140     Document Type: Article

References (81)

1. Dolznig H. Boulme F, Stangl K. et al. Establishment of normal, terminally differentiating mouse erythroid progenitors: molecular characterization by cDNA arrays. FASEB J. 2001;15:1442-1444.
2. von Lindern M, Deiner EM, Dolznig H. et al. Leukemic transformation of normal murine erythroid progenitors: v- and c-ErbB act through signaling pathways activated by the EpoR and c-Kit in stress erythropoiesis. Oncogene. 2001;20:3651-3664.
3. Bauer A, Tranche F, Wessely O, et al. The glucocorticoid receptor is required for stress erythropoiesis. Genes Dev. 1999;13:2996-3002.
4. Broudy VC, Lin NL, Priestley GV, Nocka K, Wolf NS. Interaction of stem cell factor and its receptor c-kit mediates lodgment and acute expansion of hematopoietic cells in the murine spleen. Blood. 1996;88:75-81.
5. Klingmuller U, Wu H, Hsiao JG, et al. Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. Proc Natl Acad Sci U S A. 1997;94:3016-3021.
6. Sui X, Krantz SB, Zhao ZJ. Stem cell factor and erythropoietin inhibit apoptosis of human erythroid progenitor cells through different signalling pathways. Br J Haematol. 2000;110:63-70.
7. Nishigaki K, Hanson G, Ohashi T, Thompson D, Muszynski K, Ruscetti S. Erythroid cells rendered erythropoietin independent by infection with Friend spleen focus-forming virus show constitutive activation of phosphatidylinositol 3-kinase and Akt kinase: involvement of insulin receptor substrate-related adapter proteins. J Virol. 2000; 74:3037-3045.
8. Haseyama Y, Sawada K, Oda A, et al. Phosphatidylinositol 3-kinase is involved in the protection of primary cultured human erythroid precursor cells from apoptosis. Blood. 1999;94:1568-1577.
9. Bakker WJ, Blazquez-Domingo M, Kolbus A, et al. FoxO3a regulates erythroid differentiation and induces BTG1. an activator of protein arginine methyl transferase 1. J Cell Biol. 2004;164:175-184.
10. Blazquez-Domingo M, Grech G, von Lindern M. Translation initiation factor 4E inhibits differentiation of erythroid progenitors. Mol Cell Biol. 2005; 25:8496-8506.
11. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol. 2003; 13:1259-1268.
12. Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003;17:1829-1834.
13. Dufner A, Thomas G. Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res. 1999;253:100-109.
14. Gingras AC, Gygi SP, Raught B, et al. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 1999;13:1422-1437.
15. Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell. 2005;123:569-580.
16. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001:15:807-826.
17. Gingras AC, Raught B, Sonenberg N. elF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem. 1999;68:913-963.
18. Proud CG. Signalling to translation: how signal transduction pathways control the protein synthetic machinery. Biochem J. 2007;403:217-234.
19. Kozak M. A second look at cellular mRNA sequences said to function as internal ribosome entry sites. Nucleic Acids Res. 2005;33:6593-6602.
20. Duncan R, Milburn SC, Hershey JW. Regulated phosphorylation and low abundance of HeLa cell initiation factor elF-4F suggest a role in translational control: heat shock effects on elF-4F J Biol Chem. 1987;262:380-388.
21. Sonenberg N, Gingras A-C. The mRNA 5'-binding protein elF4E and control of cell growth. Curr Opin Cell Biol. 1998;10:268-275.
22. Koromilas AE, Lazaris-Karatzas A, Sonenberg N. mRNAs containing extensive secondary structure in their 5' noncoding region translate efficiently in cells overexpressing initiation factor elF-4E. EMBO J. 1992;11:4153-4158.
23. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBOJ. 1997;16:3693-3704.
24. Wang X, Beugnet A, Murakami M, Yamanaka S, Proud GG. Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins. Mol Cell Biol. 2005;25:2558-2572.
25. Murata K, Wu J, Brautigan DL. B cell receptorassociated protein alpha4 displays rapamycinsensitive binding directly to the catalytic subunit of protein phosphatase 2A. Proc Natl Acad Sci U S A. 1997;94:10624-10629.
26. Inui S, Sanjo H, Maeda K, Yamamoto H, Miyamoto E, Sakaguchi N. Ig receptor binding protein 1 (alpha4) is associated with a rapamycinsensitive signal transduction in lymphocytes through direct binding to the catalytic subunit of protein phosphatase 2A. Blood. 1998;92:539-546.
27. Di Como CJ, Arndt KT. Nutrients, via the Tor proteins, stimulate the association of Tap42 with type 2A phosphatases. Genes Dev. 1996;10:1904-1916.
28. Kong M, Fox CJ, Mu J, et al. The PP2A-associated protein alpha4 is an essential inhibitor of apoptosis. Science. 2004;306:695-698.
29. Prickett TD, Brautigan DL. The alpha4 regulatory subunit exerts opposing allosteric effects on protein phosphatases PP6 and PP2A. J Biol Chem. 2006:281:30503-30511.
30. Liu J, PrickettTD, Elliott E, Meroni G, Brautigan DL. Phosphorylation and microtubule association of the Opitz syndrome protein mid-1 is regulated by protein phosphatase 2A via binding to the regulatory subunit alpha 4. Proc Natl Acad Sci U S A. 2001;98:6650-6655.
31. De Benedetti A, Graff JR. elF-4E expression and its role in malignancies and metastases. Oncogene. 2004;23:3189-3199.
32. De Benedetti A, Harris AL. elF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol. 1999;31:59-72.
33. Topisirovic I, Guzman ML, McConnell MJ, et al. Aberrant eukaryotic translation initiation factor 4E-dependent mRNAtransport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol. 2003;23:8992-9002.
34. Bader AG, Vogt PK. An essential role for protein synthesis in oncogenic cellular transformation. Oncogene. 2004;23:3145-3150.
35. Kowenz E, Leutz A, Doderlein G, Graf T, Beug H. ts-oncogene-transformed erythroleukemic cells: a novel test system for purifying and characterizing avian erythroid growth factors. In: Neth R, Gallo RC, Greaves MR Kabisch H, eds. Modern Trends in Human Leukemia VII. Vol. 31. Heidelberg, Germany: Springer Verlag;1987:199-209.
36. Beug H, Palmieri S, Freudenstein C, Zentgraf H. Graf T. Hormone-dependent terminal differentiation in vitro of chicken erythroleukemia cells transformed by ts mutants of avian erythroblastosis virus. Cell. 1982;28:907-919.
37. Weng L, Dai H, Zhan Y, He Y Stepaniants SB, Bassett DE. Rosetta error model for gene expression analysis. Bioinformatics. 2006:22:1111-1121.
38. van Dijk TB, van Den Akker E, Amelsvoort MP, Mano H, Lowenberg B, von Lindern M. Stem cell factor induces phosphatidylinositol 3'-kinasedependent Lyn/Tec/Dok-1 complex formation in hematopoietic cells. Blood. 2000;96:3406-3413.
39. Joosten M, Blazquez-Domingo M, Lindeboom F, et al. Translational control of putative protooncogene Nm23-M2 by cytokines via phosphoinositide 3-kinase signaling. J Biol Chem. 2004:279: 38169-38176.
40. Kolbus A, Blazquez-Domingo M, Carotta S, et al. Cooperative signaling between cytokine receptors and the glucocorticoid receptor in the expansion of erythroid progenitors: molecular analysis by expression profiling. Blood. 2003;102:3136-3146.
41. Schmidt U, van den Akker E, Parren-van Amelsvoort M, et al. Btk is required for an efficient response to erythropoietin and for SCF-controlled protection against TRAIL in erythroid progenitors. J Exp Med. 2004;199:785-795.
42. Matsuda A, Suzuki Y, Honda G, et al. Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways. Oncogene. 2003;22:3307-3318.
43. OkumuraA J, Hatsuzawa K, Tamura T, et al. Involvement of a novel Q-SNARE, D12, in quality control of the endomembrane system. J Biol Chem. 2006;281:4495-4506.
44. Bishop JD, Nien WL, Dauphinee SM, Too CK. Prolactin activates mammalian target-ofrapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells. J Endocrinol. 2006;190:307-312.
45. Peterson RT, Desai BN, Hardwick JS, Schreiber SL. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc Natl Acad Sci U S A. 1999;96:4438-4442.
46. Pradet-Balade B, Boulme F, Beug H, Mullner EW, Garcia-Sanz JA. Translation control: bridging the gap between genomics and proteomics? Trends Biochem Sci. 2001;26:225-229.
47. Grolleau A, Bowman J, Pradet-Balade B, et al. Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics. J Biol Chem. 2002;277:22175-22184.
48. Rajasekhar VK, Viale A, Socci ND, Wiedmann M, Hu X, Holland EC. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell. 2003;12:889-901.
49. Mamane Y, Petroulakis E, Martineau Y, et al. Epigenetic activation of a subset of mRNAs by elF4E explains its effects on cell proliferation. PLoS ONE. 2007;2:e242.
50. Larsson O, Li S, Issaenko OA, et al. Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res. 2007;67: 6814-6824.
51. Waerner T, Alacakaptan M, Tamir I, et al. ILEI: a cytokine essential for EMT tumor formation, and late events in metastasis in epithelial cells. Cancer Cell. 2006;10:227-239.
52. Provenzani A, Fronza R, Loreni F, Pascale A, Amadio M, Quattrone A. Global alterations in mRNA polysomal recruitment in a cell model of colorectal cancer progression to metastasis. Carcinogenesis. 2006;27:1323-1333.
53. Levy S. Avni D, Hariharan N. Perry RP. Meyuhas O. Oligopyrimidine tract at the 5'end of mammalian ribosomal protein mRNAs is required for their translational control. Proc Natl Acad Sci U S A. 1991;88:3319-3323.
54. Thomson AM, Rogers JT, Leedman PJ. Ironregulatory proteins, iron-responsive elements and ferritin mRNA translation. Int J Biochem Cell Biol. 1999;31:1139-1152.
55. Darnell JC, Fraser CE, Mostovetsky O, et al. Kissing complex RNAs mediate interaction between the Fragile-X mental retardation protein KH2 domain and brain polyribosomes. Genes Dev. 2005;19:903-918.
56. Child SJ, Miller MK, Geballe AP. Translational control by an upstream open reading frame in the HER-2/neu transcript. J Biol Chem. 1999;274: 24335-24341.
57. Kozak M. Effects of intercistronic length on the efficiency of reinitiation by eucaryotic ribosomes. Mol Cell Biol. 1987;7:3438-3445.
58. Hara K, Yonezawa K, Weng Q-P, Kozlowski MT, Belham C, Avruch J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and elF-4E BP1 through a common effector mechanism. J Biol Chem. 1998;273:14484-14494.
59. Lawrence JC Jr, Fadden P. Haystead TA, Lin TA. PHAS proteins as mediators of the actions of insulin, growth factors and cAMP on protein synthesis and cell proliferation. Adv Enzyme Regul. 1997;37:239-267.
60. Kloeker S, Reed R, McConnell JL, et al. Parallel purification of three catalytic subunits of the protein serine/threonine phosphatase 2Afamily (PP2A(C), PP4(C), and PP6(C)) and analysis of the interaction of PP2A(C) with alpha4 protein. Protein Expr Purif. 2003;31:19-33.
61. Sontag E. Protein phosphatase 2A: the Trojan Horse of cellular signaling. Cell Signal. 2001;13: 7-16.
62. Yoo SJ, Boylan JM, Brautigan DL, Gruppuso PA. Subunit composition and developmental regulation of hepatic protein phosphatase 2A(PP2A). Arch Biochem Biophys. 2007;461:186-193.
63. Kamibayashi C, Estes R, Lickteig RL, Yang SI, Craft C, Mumby MC. Comparison of heterotrimeric protein phosphatase 2A containing different Bsubunits. J Biol Chem. 1994;269:20139-20148.
64. Petritsch C, Beug H, Balmain A, Oft M. TGF-beta inhibits p70 S6 kinase via protein phosphatase 2A to induce G1 arrest. Genes Dev. 2000;14: 3093-3101.
65. von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A, Grosveld G. Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene. Mol Cell Biol. 1992;12:3346-3355.
66. Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 2005;8:355-368.
67. Yang G, Huang SC, Wu JY, Benz EJ Jr. An erythroid differentiation- specific splicing switch in protein 4.1 R mediated by the interaction of SF2/ASF with an exonic splicing enhancer. Blood. 2005;105:2146-2153.
68. Hou VC, Lersch R, Gee SL, et al. Decrease in hnRNP A/B expression during erythropoiesis mediates a pre-mRNA splicing switch. EMBO J. 2002;21:6195-6204.
69. Caceres JF, Kornblihtt AR. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet. 2002;18:186-193.
70. MaucuerA, Ozon S, Manceau V. et al. KIS is a protein kinase with an RNA recognition motif. J Biol Chem. 1997;272:23151-23156.
71. Roth S, Neuman-Silberberg FS, Barcelo G, Schupbach T. cornichon and the EGF receptor signaling process are necessary for both anteriorposterior and dorsal-ventral pattern formation in Drosophila. Cell. 1995;81:967-978.
72. Duan JZ, Zhang JP, Zhu SX. mED2: a novel gene involved in mouse embryonic development. Yi Chuan Xue Bao. 2006;33:692-701.
73. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U SA. 2001;98:10314-10319.
74. Min YH, Eom Jl, Cheong JW, et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia. 2003;17:995-997.
75. Grandage VL, Gale RE, Linch DC, Khwaja A. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia. 2005;19:586-594.
76. Sujobert P, Bardet V, Cornillet-Lefebvre P, et al. Essential role for the pHOdelta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood. 2005:106: 1063-1066.
77. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489-501.
78. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4:257-262.
79. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004; 4:335-348.
80. Hidalgo M, Rowinsky EK. The rapamycinsensitive signal transduction pathway as a target for cancer therapy. Oncogene. 2000;19:6680-6686.
81. Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer. 2004:100:657-666.